Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-01-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT00042978
Locations
🇺🇸

Cancer and Leukemia Group B, Chicago, Illinois, United States

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

First Posted Date
2003-01-27
Last Posted Date
2020-10-22
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
397
Registration Number
NCT00004054
Locations
🇺🇸

Lutheran General Cancer Care Center, Park Ridge, Illinois, United States

🇺🇸

Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States

🇺🇸

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

and more 51 locations

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2010-10-01
Lead Sponsor
Temple University
Registration Number
NCT00002522
Locations
🇺🇸

Fox Chase - Temple Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2010-10-01
Lead Sponsor
Temple University
Registration Number
NCT00002521
Locations
🇺🇸

Fox Chase - Temple Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

First Posted Date
2003-01-27
Last Posted Date
2014-01-09
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
4
Registration Number
NCT00041015
Locations
🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

First Posted Date
2003-01-27
Last Posted Date
2017-02-23
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
48
Registration Number
NCT00002931
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

First Posted Date
2003-01-27
Last Posted Date
2014-02-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
220
Registration Number
NCT00022737
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2013-09-17
Lead Sponsor
EBMT Solid Tumors Working Party
Target Recruit Count
460
Registration Number
NCT00005589
Locations
🇩🇪

Universitaetsklinikum Goettingen, Goettingen, Germany

🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

and more 128 locations

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2021-08-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
361
Registration Number
NCT00003816
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

First Posted Date
2003-01-27
Last Posted Date
2019-04-25
Lead Sponsor
Children's Hospital of Philadelphia
Target Recruit Count
30
Registration Number
NCT00031590
Locations
🇺🇸

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy